董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kleanthis G. Xanthopoulos | 男 | Chairman of the Board | 65 | 14.91万美元 | 25.24 | 2025-12-17 |
| Barry Quart | 男 | Chief Executive Officer and Director | 68 | 452.14万美元 | 13.19 | 2025-12-17 |
| Jean Liu | 女 | Director | 56 | 8.60万美元 | 10.30 | 2025-12-17 |
| Karen J. Wilson | 女 | Director | 61 | 9.10万美元 | 16.82 | 2025-12-17 |
| James Zuie chin Huang | 男 | Director | 59 | 未披露 | 1376.00 | 2025-12-17 |
| James A. Schoeneck | 男 | Director | 67 | 未披露 | 未持股 | 2025-12-17 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Barry Quart | 男 | Chief Executive Officer and Director | 68 | 452.14万美元 | 13.19 | 2025-12-17 |
| 孙雷 | 男 | Vice President, Biologics and Head of CMC | 61 | 未披露 | 未持股 | 2025-12-17 |
| David Szekeres | 男 | President | 52 | 314.91万美元 | 16.09 | 2025-12-17 |
| Lisa Peraza | 女 | Vice President, Finance | 48 | 60.87万美元 | 未持股 | 2025-12-17 |
| Jeff Cohn | 男 | General Counsel and Corporate Secretary | 43 | 未披露 | 未持股 | 2025-12-17 |
| Raúl Collazo | 男 | Vice President, Global Medical Affairs | 58 | 未披露 | 未持股 | 2025-12-17 |
| Kimberly J. Manhard | 女 | Executive Vice President, Chief Development Officer | 65 | 未披露 | 未持股 | 2025-12-17 |
董事简历
中英对照 | 中文 | 英文- Kleanthis G. Xanthopoulos
-
Kleanthis G. Xanthopoulos自2020年12月起担任互联生物制药控股有限公司董事会成员。Xanthopoulos博士目前是Irras AB的首席执行官，也是Stork Capital Life Sciences的董事长，Stork Capital Life Sciences专注于创新生物技术公司的建设和投资，Xanthopoulos博士曾于2015年至2020年担任CERUS DMCC的管理普通合伙人。他是生物技术和医药研究领域经验丰富、富有远见的领导者，在运营和企业发展方面有着坚实的基础。他现任Regulus Therapeutics 的总裁、首席执行官、董事。2007年加入 Regulus Therapeutics 之前，他是Enterprise Partners Venture Capital的管理合伙人。他联合创办了Anadys Pharmaceuticals，并于2000-2006年间担任总裁兼首席执行官，在该公司于2011年被罗氏收购之前一直担任董事。在此之前，1997-2000，他担任被Vertex Pharmaceuticals 收购的Aurora Biosciences的副总裁；1995-1997，担任国家人类基因组研究所的部门总监。此前，他是瑞典斯德哥尔摩卡罗林斯卡研究所的副教授在。他现任生物技术工业组织（BIO）、Regulus Therapeutics（纳斯达克代码：RGLS）、 Zosano Pharma的董事会成员，也是Sente, Inc的共同创始人和董事。此外，他获得了2006年安永健康科学年度企业家的荣誉，并于2013年被圣迭戈商业杂志评为最受尊敬的首席执行官。他也是奥纳西斯基金会学者，他获得了希腊塞萨洛尼基亚里士多德大学的生物学荣誉学士学位，瑞典斯德哥尔摩大学的微生物学硕士学位和分子生物学博士学位，以及纽约洛克菲勒大学的博士后研究奖学金。
Kleanthis G. Xanthopoulos,has served on Board since 2020 and was appointed as Chairman in 2024. Dr. Xanthopoulos has over 28 years of experience in the biotechnology and pharmaceutical research industries as an executive, company founder, chief executive officer, investor, and member of various boards of directors. Dr. Xanthopoulos has served as Chairman & Chief Executive Officer of Shoreline Biosciences, Inc. and Chairman of Stork Capital Life Sciences, which focuses on building and investing in innovative biotechnology companies, since 2020. He previously served as Chief Executive Officer of IRRAS AB and President and Chief Executive Officer of Regulus Therapeutics, Inc. He also previously served on the board of directors of Zosano Pharma Corporation. Dr. Xanthopoulos is an Onassis Scholar and was at NIH Human Genome Research Institute. Dr. Xanthopoulos received a B.S. in Biology from Aristotle University of Thessaloniki, Greece, an M.Sc. in Microbiology, and a Ph.D. in Molecular Biology from the University of Stockholm, Sweden. - Kleanthis G. Xanthopoulos自2020年12月起担任互联生物制药控股有限公司董事会成员。Xanthopoulos博士目前是Irras AB的首席执行官，也是Stork Capital Life Sciences的董事长，Stork Capital Life Sciences专注于创新生物技术公司的建设和投资，Xanthopoulos博士曾于2015年至2020年担任CERUS DMCC的管理普通合伙人。他是生物技术和医药研究领域经验丰富、富有远见的领导者，在运营和企业发展方面有着坚实的基础。他现任Regulus Therapeutics 的总裁、首席执行官、董事。2007年加入 Regulus Therapeutics 之前，他是Enterprise Partners Venture Capital的管理合伙人。他联合创办了Anadys Pharmaceuticals，并于2000-2006年间担任总裁兼首席执行官，在该公司于2011年被罗氏收购之前一直担任董事。在此之前，1997-2000，他担任被Vertex Pharmaceuticals 收购的Aurora Biosciences的副总裁；1995-1997，担任国家人类基因组研究所的部门总监。此前，他是瑞典斯德哥尔摩卡罗林斯卡研究所的副教授在。他现任生物技术工业组织（BIO）、Regulus Therapeutics（纳斯达克代码：RGLS）、 Zosano Pharma的董事会成员，也是Sente, Inc的共同创始人和董事。此外，他获得了2006年安永健康科学年度企业家的荣誉，并于2013年被圣迭戈商业杂志评为最受尊敬的首席执行官。他也是奥纳西斯基金会学者，他获得了希腊塞萨洛尼基亚里士多德大学的生物学荣誉学士学位，瑞典斯德哥尔摩大学的微生物学硕士学位和分子生物学博士学位，以及纽约洛克菲勒大学的博士后研究奖学金。
- Kleanthis G. Xanthopoulos,has served on Board since 2020 and was appointed as Chairman in 2024. Dr. Xanthopoulos has over 28 years of experience in the biotechnology and pharmaceutical research industries as an executive, company founder, chief executive officer, investor, and member of various boards of directors. Dr. Xanthopoulos has served as Chairman & Chief Executive Officer of Shoreline Biosciences, Inc. and Chairman of Stork Capital Life Sciences, which focuses on building and investing in innovative biotechnology companies, since 2020. He previously served as Chief Executive Officer of IRRAS AB and President and Chief Executive Officer of Regulus Therapeutics, Inc. He also previously served on the board of directors of Zosano Pharma Corporation. Dr. Xanthopoulos is an Onassis Scholar and was at NIH Human Genome Research Institute. Dr. Xanthopoulos received a B.S. in Biology from Aristotle University of Thessaloniki, Greece, an M.Sc. in Microbiology, and a Ph.D. in Molecular Biology from the University of Stockholm, Sweden.
- Barry Quart
-
Barry Quart，于2024年6月被任命为首席执行官兼董事。他拥有超过30年的丰富经验，在生物技术和制药公司担任领导职务，并开发创新制药产品。他最近担任Heron Therapeutics， Inc.的首席执行官和董事会主席，直到2023年。在2012年加入Heron之前，他共同创立了Ardea Biosciences， Inc.，并担任其总裁、首席执行官和董事（从2006年成立到2012年被AstraZeneca PLC收购）。他目前担任Kiniksa Pharmaceuticals Corp.的董事会成员。他获得了药学博士学位，来自加州大学旧金山分校。
Barry Quart,was appointed Chief Executive Officer and Director in June 2024. Dr. Quart has over 30 years of extensive experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. Dr. Quart was most recently Chief Executive Officer and Chairman of the board of directors of Heron Therapeutics, Inc. until 2023. Prior to joining Heron in 2012, Dr. Quart co-founded Ardea Biosciences, Inc. and served as its President and Chief Executive Officer and Director from its inception in 2006 through its acquisition by AstraZeneca PLC in 2012. Dr. Quart currently serves on the board of directors of Kiniksa Pharmaceuticals Corp. Dr. Quart received his Pharm.D. from the University of California, San Francisco. - Barry Quart，于2024年6月被任命为首席执行官兼董事。他拥有超过30年的丰富经验，在生物技术和制药公司担任领导职务，并开发创新制药产品。他最近担任Heron Therapeutics， Inc.的首席执行官和董事会主席，直到2023年。在2012年加入Heron之前，他共同创立了Ardea Biosciences， Inc.，并担任其总裁、首席执行官和董事（从2006年成立到2012年被AstraZeneca PLC收购）。他目前担任Kiniksa Pharmaceuticals Corp.的董事会成员。他获得了药学博士学位，来自加州大学旧金山分校。
- Barry Quart,was appointed Chief Executive Officer and Director in June 2024. Dr. Quart has over 30 years of extensive experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. Dr. Quart was most recently Chief Executive Officer and Chairman of the board of directors of Heron Therapeutics, Inc. until 2023. Prior to joining Heron in 2012, Dr. Quart co-founded Ardea Biosciences, Inc. and served as its President and Chief Executive Officer and Director from its inception in 2006 through its acquisition by AstraZeneca PLC in 2012. Dr. Quart currently serves on the board of directors of Kiniksa Pharmaceuticals Corp. Dr. Quart received his Pharm.D. from the University of California, San Francisco.
- Jean Liu
-
Jean Liu，自2021年起担任董事。她拥有超过25年的生物制药执行和律师事务所经验，最近担任Seagen Inc.（靶向癌症治疗公司，于2023年12月被辉瑞收购）的首席法律官和秘书。在2014年加入Seagen之前，她曾担任Halozyme Therapeutics， Inc.和Durect Corporation的高级法律领导职务，包括总法律顾问、合规主管和首席法律官。Liu女士目前担任Erasca， Inc.的董事会成员。在加入生物制药行业之前，她是Pillsbury LLP和Venture law Group律师事务所的律师。她获得了哥伦比亚大学法学院的法学博士学位和斯坦福大学的分子生物学硕士学位。
Jean Liu,has served on Board since 2021. Ms. Liu has more than 25 years of biopharmaceutical executive and law firm experience and was most recently Chief Legal Officer and Secretary of Seagen Inc., a targeted cancer therapeutic company which was acquired by Pfizer in December 2023. Prior to joining Seagen in 2014, she served in senior legal leadership roles at Halozyme Therapeutics, Inc. and Durect Corporation, including General Counsel, Head of Compliance and Chief Legal Officer. Ms. Liu currently serves on the board of directors of Erasca, Inc. Before joining the biopharmaceutical industry, Ms. Liu was an attorney at the law firms of Pillsbury LLP and Venture Law Group. Ms. Liu received her J.D. from Columbia University School of Law and her M.S. in Molecular Biology from Stanford University. - Jean Liu，自2021年起担任董事。她拥有超过25年的生物制药执行和律师事务所经验，最近担任Seagen Inc.（靶向癌症治疗公司，于2023年12月被辉瑞收购）的首席法律官和秘书。在2014年加入Seagen之前，她曾担任Halozyme Therapeutics， Inc.和Durect Corporation的高级法律领导职务，包括总法律顾问、合规主管和首席法律官。Liu女士目前担任Erasca， Inc.的董事会成员。在加入生物制药行业之前，她是Pillsbury LLP和Venture law Group律师事务所的律师。她获得了哥伦比亚大学法学院的法学博士学位和斯坦福大学的分子生物学硕士学位。
- Jean Liu,has served on Board since 2021. Ms. Liu has more than 25 years of biopharmaceutical executive and law firm experience and was most recently Chief Legal Officer and Secretary of Seagen Inc., a targeted cancer therapeutic company which was acquired by Pfizer in December 2023. Prior to joining Seagen in 2014, she served in senior legal leadership roles at Halozyme Therapeutics, Inc. and Durect Corporation, including General Counsel, Head of Compliance and Chief Legal Officer. Ms. Liu currently serves on the board of directors of Erasca, Inc. Before joining the biopharmaceutical industry, Ms. Liu was an attorney at the law firms of Pillsbury LLP and Venture Law Group. Ms. Liu received her J.D. from Columbia University School of Law and her M.S. in Molecular Biology from Stanford University.
- Karen J. Wilson
-
Karen J. Wilson，自2021年3月起担任非执行董事。她目前在Angion Biomedica、Connect Biopharma和Vaxart, Inc.等多家上市公司的董事会任职。Wilson女士曾担任Jazz Pharmaceuticals plc财务高级副总裁，直至2020年9月，此前曾担任财务副总裁兼首席会计官。在2011年2月加入爵士制药之前，Wilson女士曾在PDL BioPharma, Inc.担任财务副总裁兼首席会计官。她之前还曾担任Wilson Crisler LLC咨询公司的负责人、ViroLogic公司的首席财务官、Novare Surgical Systems公司的首席财务官和运营副总裁，以及德勤会计师事务所的顾问和审计师。Wilson女士是一名注册会计师，在加州大学伯克利分校获得商学学士学位。
Karen J. Wilson,has served as a non-executive director since March 2021. She currently serves on the board of directors of Elicio Therapeutics since March 2020 (formerly Angion Biomedica), Connect Biopharma since December 2020, and Serina Therapeutics since January 2025, and previously served on the board of directors of Vaxart, Inc. from August 2020 to August 2022. Ms. Wilson served as Senior Vice President of Finance at Jazz Pharmaceuticals plc until September 2020 after serving as Vice President of Finance and Principal Accounting Officer. Prior to joining Jazz Pharmaceuticals in February 2011, Ms. Wilson served as Vice President of Finance and Principal Accounting Officer at PDL BioPharma, Inc. She also previously served as a Principal at the consulting firm of Wilson Crisler LLC, Chief Financial Officer of ViroLogic, Inc., Chief Financial Officer and Vice President of Operations for Novare Surgical Systems, Inc., and as a consultant and auditor for Deloitte & Touche LLP. Ms. Wilson is a Certified Public Accountant and received a B.S. in Business from the University of California, Berkeley. - Karen J. Wilson，自2021年3月起担任非执行董事。她目前在Angion Biomedica、Connect Biopharma和Vaxart, Inc.等多家上市公司的董事会任职。Wilson女士曾担任Jazz Pharmaceuticals plc财务高级副总裁，直至2020年9月，此前曾担任财务副总裁兼首席会计官。在2011年2月加入爵士制药之前，Wilson女士曾在PDL BioPharma, Inc.担任财务副总裁兼首席会计官。她之前还曾担任Wilson Crisler LLC咨询公司的负责人、ViroLogic公司的首席财务官、Novare Surgical Systems公司的首席财务官和运营副总裁，以及德勤会计师事务所的顾问和审计师。Wilson女士是一名注册会计师，在加州大学伯克利分校获得商学学士学位。
- Karen J. Wilson,has served as a non-executive director since March 2021. She currently serves on the board of directors of Elicio Therapeutics since March 2020 (formerly Angion Biomedica), Connect Biopharma since December 2020, and Serina Therapeutics since January 2025, and previously served on the board of directors of Vaxart, Inc. from August 2020 to August 2022. Ms. Wilson served as Senior Vice President of Finance at Jazz Pharmaceuticals plc until September 2020 after serving as Vice President of Finance and Principal Accounting Officer. Prior to joining Jazz Pharmaceuticals in February 2011, Ms. Wilson served as Vice President of Finance and Principal Accounting Officer at PDL BioPharma, Inc. She also previously served as a Principal at the consulting firm of Wilson Crisler LLC, Chief Financial Officer of ViroLogic, Inc., Chief Financial Officer and Vice President of Operations for Novare Surgical Systems, Inc., and as a consultant and auditor for Deloitte & Touche LLP. Ms. Wilson is a Certified Public Accountant and received a B.S. in Business from the University of California, Berkeley.
- James Zuie chin Huang
-
James Zuie chin Huang，拥有超过30年的生物技术经验。自2018年以来，他一直担任Panacea Venture的创始合伙人，这是一家投资公司，专注于全球范围内的创新和变革性医疗保健和生命科学公司。在此之前，Huang先生曾在Kleiner Perkins（KPCB）China和Vivo Ventures担任管理合伙人，并曾在Anesiva，Inc.、Tularik Inc.、GlaxoSmithKline LLC、百时美施贵宝公司和ALZA Corporation担任多个领导职务。Huang先生担任Kindstar GlobalGene Technology，Inc.和Lee's Pharmaceutical（HK）Limited的董事会成员。此前，Huang先生曾在CASI制药公司、Windtree Therapeutics，Inc.和Alaunos Therapeutics, Inc.的董事会任职。Huang先生曾获得斯坦福大学工商管理硕士学位和加州大学伯克利分校化学工程学士学位。
James Zuie chin Huang,has over 30 years of biotech experience. He has served as the Founding Partner of Panacea Venture, an investment firm with its focus on innovative and transformative healthcare and life sciences companies worldwide, since 2018. Prior to that, Mr. Huang served as managing partner at Kleiner Perkins (KPCB) China and at Vivo Ventures, and he served in various leadership roles with Anesiva, Inc., Tularik Inc., GlaxoSmithKline LLC, Bristol-Myers Squibb Company and ALZA Corporation. Mr. Huang serves on the boards of directors of Kindstar Globalgene Technology, Inc. and Lee's Pharmaceutical (HK) Limited. Previously, Mr. Huang served on the boards of directors of Casi Pharmaceuticals, Inc., Windtree Therapeutics, Inc. and Alaunos Therapeutics, Inc. Mr. Huang received an M.B.A. from Stanford and a B.S. degree in chemical engineering from University of California, Berkeley. - James Zuie chin Huang，拥有超过30年的生物技术经验。自2018年以来，他一直担任Panacea Venture的创始合伙人，这是一家投资公司，专注于全球范围内的创新和变革性医疗保健和生命科学公司。在此之前，Huang先生曾在Kleiner Perkins（KPCB）China和Vivo Ventures担任管理合伙人，并曾在Anesiva，Inc.、Tularik Inc.、GlaxoSmithKline LLC、百时美施贵宝公司和ALZA Corporation担任多个领导职务。Huang先生担任Kindstar GlobalGene Technology，Inc.和Lee's Pharmaceutical（HK）Limited的董事会成员。此前，Huang先生曾在CASI制药公司、Windtree Therapeutics，Inc.和Alaunos Therapeutics, Inc.的董事会任职。Huang先生曾获得斯坦福大学工商管理硕士学位和加州大学伯克利分校化学工程学士学位。
- James Zuie chin Huang,has over 30 years of biotech experience. He has served as the Founding Partner of Panacea Venture, an investment firm with its focus on innovative and transformative healthcare and life sciences companies worldwide, since 2018. Prior to that, Mr. Huang served as managing partner at Kleiner Perkins (KPCB) China and at Vivo Ventures, and he served in various leadership roles with Anesiva, Inc., Tularik Inc., GlaxoSmithKline LLC, Bristol-Myers Squibb Company and ALZA Corporation. Mr. Huang serves on the boards of directors of Kindstar Globalgene Technology, Inc. and Lee's Pharmaceutical (HK) Limited. Previously, Mr. Huang served on the boards of directors of Casi Pharmaceuticals, Inc., Windtree Therapeutics, Inc. and Alaunos Therapeutics, Inc. Mr. Huang received an M.B.A. from Stanford and a B.S. degree in chemical engineering from University of California, Berkeley.
- James A. Schoeneck
-
2011年4月，James A. Schoeneck加入公司并总裁兼首席执行官。2007年12月以来，他担任该公司董事。从2005年直到他加入公司，他担任BrainCells的首席执行官，一家民营生物制药公司。加入BrainCells之前，他担任ActivX生物科学公司的首席执行官，一家开发阶段的生物技术公司。他的制药经验还包括担任普罗米修斯实验室的总裁兼首席执行官3年。加入Prometheus之前，他在Centocor工作3年，他领导Centocor的商业能力发展。他的团队推出Remicade，这已成为世界上最大的药品之一。在他职业生涯的早期，他在Rhone-Poulenc Rorer工作13年，现在是Sanofi公司。他从事各种销售和营销职位。
James A. Schoeneck has served on the company's board of directors since April 2010. He joined Depomed, Inc., a pharmaceutical company, as a director in 2007 and became President and Chief Executive Officer of Depomed in April 2011 serving until March 2017. From 2005 until he joined Depomed, Inc. in April 2011 Mr. Schoeneck was Chief Executive Officer of BrainCells Inc., a privately-held biopharmaceutical company. Prior to joining BrainCells Inc., he served as Chief Executive Officer of ActivX BioSciences, a development stage biotechnology company. Mr. Schoeneck’s pharmaceutical experience also includes three years as President and Chief Executive Officer of Prometheus Laboratories Inc., a pharmaceutical and diagnostics company. Prior to joining Prometheus, Mr. Schoeneck spent three years as vice president and General Manager, Immunology, at Centocor, Inc. now Janssen Biotech, Inc., a biotechnology company, where he led the development of Centocor’s commercial capabilities. His group launched Remicade ® became one of the world’s largest pharmaceutical products. Earlier in his career, he spent 13 years at Rhone-Poulenc Rorer, Inc. (now Sanofi), a pharmaceutical company, serving in various sales and marketing positions of increasing responsibility. Mr. Schoeneck holds a B.S. in Education from Jacksonville State University. - 2011年4月，James A. Schoeneck加入公司并总裁兼首席执行官。2007年12月以来，他担任该公司董事。从2005年直到他加入公司，他担任BrainCells的首席执行官，一家民营生物制药公司。加入BrainCells之前，他担任ActivX生物科学公司的首席执行官，一家开发阶段的生物技术公司。他的制药经验还包括担任普罗米修斯实验室的总裁兼首席执行官3年。加入Prometheus之前，他在Centocor工作3年，他领导Centocor的商业能力发展。他的团队推出Remicade，这已成为世界上最大的药品之一。在他职业生涯的早期，他在Rhone-Poulenc Rorer工作13年，现在是Sanofi公司。他从事各种销售和营销职位。
- James A. Schoeneck has served on the company's board of directors since April 2010. He joined Depomed, Inc., a pharmaceutical company, as a director in 2007 and became President and Chief Executive Officer of Depomed in April 2011 serving until March 2017. From 2005 until he joined Depomed, Inc. in April 2011 Mr. Schoeneck was Chief Executive Officer of BrainCells Inc., a privately-held biopharmaceutical company. Prior to joining BrainCells Inc., he served as Chief Executive Officer of ActivX BioSciences, a development stage biotechnology company. Mr. Schoeneck’s pharmaceutical experience also includes three years as President and Chief Executive Officer of Prometheus Laboratories Inc., a pharmaceutical and diagnostics company. Prior to joining Prometheus, Mr. Schoeneck spent three years as vice president and General Manager, Immunology, at Centocor, Inc. now Janssen Biotech, Inc., a biotechnology company, where he led the development of Centocor’s commercial capabilities. His group launched Remicade ® became one of the world’s largest pharmaceutical products. Earlier in his career, he spent 13 years at Rhone-Poulenc Rorer, Inc. (now Sanofi), a pharmaceutical company, serving in various sales and marketing positions of increasing responsibility. Mr. Schoeneck holds a B.S. in Education from Jacksonville State University.
高管简历
中英对照 | 中文 | 英文- Barry Quart
Barry Quart，于2024年6月被任命为首席执行官兼董事。他拥有超过30年的丰富经验，在生物技术和制药公司担任领导职务，并开发创新制药产品。他最近担任Heron Therapeutics， Inc.的首席执行官和董事会主席，直到2023年。在2012年加入Heron之前，他共同创立了Ardea Biosciences， Inc.，并担任其总裁、首席执行官和董事（从2006年成立到2012年被AstraZeneca PLC收购）。他目前担任Kiniksa Pharmaceuticals Corp.的董事会成员。他获得了药学博士学位，来自加州大学旧金山分校。
Barry Quart,was appointed Chief Executive Officer and Director in June 2024. Dr. Quart has over 30 years of extensive experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. Dr. Quart was most recently Chief Executive Officer and Chairman of the board of directors of Heron Therapeutics, Inc. until 2023. Prior to joining Heron in 2012, Dr. Quart co-founded Ardea Biosciences, Inc. and served as its President and Chief Executive Officer and Director from its inception in 2006 through its acquisition by AstraZeneca PLC in 2012. Dr. Quart currently serves on the board of directors of Kiniksa Pharmaceuticals Corp. Dr. Quart received his Pharm.D. from the University of California, San Francisco.- Barry Quart，于2024年6月被任命为首席执行官兼董事。他拥有超过30年的丰富经验，在生物技术和制药公司担任领导职务，并开发创新制药产品。他最近担任Heron Therapeutics， Inc.的首席执行官和董事会主席，直到2023年。在2012年加入Heron之前，他共同创立了Ardea Biosciences， Inc.，并担任其总裁、首席执行官和董事（从2006年成立到2012年被AstraZeneca PLC收购）。他目前担任Kiniksa Pharmaceuticals Corp.的董事会成员。他获得了药学博士学位，来自加州大学旧金山分校。
- Barry Quart,was appointed Chief Executive Officer and Director in June 2024. Dr. Quart has over 30 years of extensive experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. Dr. Quart was most recently Chief Executive Officer and Chairman of the board of directors of Heron Therapeutics, Inc. until 2023. Prior to joining Heron in 2012, Dr. Quart co-founded Ardea Biosciences, Inc. and served as its President and Chief Executive Officer and Director from its inception in 2006 through its acquisition by AstraZeneca PLC in 2012. Dr. Quart currently serves on the board of directors of Kiniksa Pharmaceuticals Corp. Dr. Quart received his Pharm.D. from the University of California, San Francisco.
- 孙雷
孙雷自2020年1月起担任互联生物制药控股有限公司的生物制剂副总裁兼CMC负责人。此前，孙博士曾于2008年1月至2019年5月在Autekbio，Inc.担任首席技术官和制造副总裁。在担任这一职务之前，孙博士于2005年1月至2007年12月在Percivia支持药物开发，2003年1月至2004年12月在Shire PLC，2001年1月至2002年12月在UCB S.A.。孙博士在哈佛医学院完成分子免疫学博士后培训，在明尼苏达大学获得分子生物学和生物化学博士学位，在南开大学获得生物化学学士学位，是皇家帝斯曼公司（Royal DSM N.V。）和Crucell N.V。的合资企业Percivia的创始成员。
Lei Sun,has served as Vice President of Biologics and Head of CMC since January 2020. Dr. Sun has over 25 years of experience in pharmaceutical development of biologics focused on process development, CMC, and manufacturing operations. Prior to joining Connect, Dr. Sun served as Chief Technology Officer and Vice President of Manufacturing at AutekBio, Inc. Prior to that, Dr. Sun supported drug development at PERVICIA, UCB Pharma, Shire Pharmaceuticals and DSM/Crucell JV. Dr. Sun has more than 20 publications in peer-reviewed journals and was an inventor of multiple patents in biologics and process development. He received his Ph.D. in molecular biology and biochemistry from the University of Minnesota and completed his postdoctoral training in molecular immunology at Harvard Medical School.- 孙雷自2020年1月起担任互联生物制药控股有限公司的生物制剂副总裁兼CMC负责人。此前，孙博士曾于2008年1月至2019年5月在Autekbio，Inc.担任首席技术官和制造副总裁。在担任这一职务之前，孙博士于2005年1月至2007年12月在Percivia支持药物开发，2003年1月至2004年12月在Shire PLC，2001年1月至2002年12月在UCB S.A.。孙博士在哈佛医学院完成分子免疫学博士后培训，在明尼苏达大学获得分子生物学和生物化学博士学位，在南开大学获得生物化学学士学位，是皇家帝斯曼公司（Royal DSM N.V。）和Crucell N.V。的合资企业Percivia的创始成员。
- Lei Sun,has served as Vice President of Biologics and Head of CMC since January 2020. Dr. Sun has over 25 years of experience in pharmaceutical development of biologics focused on process development, CMC, and manufacturing operations. Prior to joining Connect, Dr. Sun served as Chief Technology Officer and Vice President of Manufacturing at AutekBio, Inc. Prior to that, Dr. Sun supported drug development at PERVICIA, UCB Pharma, Shire Pharmaceuticals and DSM/Crucell JV. Dr. Sun has more than 20 publications in peer-reviewed journals and was an inventor of multiple patents in biologics and process development. He received his Ph.D. in molecular biology and biochemistry from the University of Minnesota and completed his postdoctoral training in molecular immunology at Harvard Medical School.
- David Szekeres
David Szekeres，曾担任Gri Bio, Inc.的成员。自2009年4月起担任董事。Szekeres于2016年3月加入Heron Therapeutics, Inc.，担任首席运营官和财务主管。在此之前，他曾担任Regulus Therapeutics Inc.的首席商务官、首席财务官和总法律顾问（2014年至2016年）。从2008年到2014年2月被Thermo Fisher Scientific收购，他还担任Life Technologies Corporation的并购、证券和治理主管。2006年至2008年，他曾担任多家律师事务所（包括Latham & Watkins LLP）的公司律师。他目前担任Sanford Burnham Prebys的董事会成员。他从2014年3月起担任Edico Genome Inc.的董事会成员，直到2018年被Illumina收购；从2014年10月起担任Patara Pharma的董事会成员，直到2018年被Roivant Sciences收购。他持有加州大学欧文分校（University of California, Irvine）的犯罪学、法律和社会学士学位，以及杜克大学法学院（Duke University School of law）的法学博士学位。
David Szekeres has served as a member of Board since April 2023. Mr. Szekeres currently serves as the President of Connect Biopharma Holdings Limited, a publicly traded, U.S. headquartered global clinical stage biopharmaceutical company (NASDAQ: CNTB), a position he has held since June 2024. He has more than two decades of experience in the global life sciences indtry as a finance and biness development executive, deal maker, legal counsel and board member. Mr. Szekeres joined Heron Therapeutics, Inc. in March 2016 and served as Chief Operating Officer and Head of Finance until Augt 2023. Prior to this, he served as Chief Biness Officer, Principal Financial & Accounting Officer and General Counsel at Regul Therapeutics Inc. from 2014 to 2016. Mr. Szekeres also served as head of Mergers and Acquisitions at Life Technologies Corporation from 2008 through its acquisition by Thermo Fisher Scientific in February 2014. Mr. Szekeres currently serves on the board of directors at Sanford Burnham Prebys, CureMatch, and Animantis, and as an executive advisory board member at Colossal Biosciences. He served on the board of directors of Edico Genome Inc. from March 2014 until its acquisition by Illumina in 2018 and Patara Pharma from October 2014 until its acquisition by Roivant Sciences in 2018. Mr. Szekeres received his undergraduate degree in criminology, law and society from the University of California, Irvine and his J.D. from Duke University School of Law.- David Szekeres，曾担任Gri Bio, Inc.的成员。自2009年4月起担任董事。Szekeres于2016年3月加入Heron Therapeutics, Inc.，担任首席运营官和财务主管。在此之前，他曾担任Regulus Therapeutics Inc.的首席商务官、首席财务官和总法律顾问（2014年至2016年）。从2008年到2014年2月被Thermo Fisher Scientific收购，他还担任Life Technologies Corporation的并购、证券和治理主管。2006年至2008年，他曾担任多家律师事务所（包括Latham & Watkins LLP）的公司律师。他目前担任Sanford Burnham Prebys的董事会成员。他从2014年3月起担任Edico Genome Inc.的董事会成员，直到2018年被Illumina收购；从2014年10月起担任Patara Pharma的董事会成员，直到2018年被Roivant Sciences收购。他持有加州大学欧文分校（University of California, Irvine）的犯罪学、法律和社会学士学位，以及杜克大学法学院（Duke University School of law）的法学博士学位。
- David Szekeres has served as a member of Board since April 2023. Mr. Szekeres currently serves as the President of Connect Biopharma Holdings Limited, a publicly traded, U.S. headquartered global clinical stage biopharmaceutical company (NASDAQ: CNTB), a position he has held since June 2024. He has more than two decades of experience in the global life sciences indtry as a finance and biness development executive, deal maker, legal counsel and board member. Mr. Szekeres joined Heron Therapeutics, Inc. in March 2016 and served as Chief Operating Officer and Head of Finance until Augt 2023. Prior to this, he served as Chief Biness Officer, Principal Financial & Accounting Officer and General Counsel at Regul Therapeutics Inc. from 2014 to 2016. Mr. Szekeres also served as head of Mergers and Acquisitions at Life Technologies Corporation from 2008 through its acquisition by Thermo Fisher Scientific in February 2014. Mr. Szekeres currently serves on the board of directors at Sanford Burnham Prebys, CureMatch, and Animantis, and as an executive advisory board member at Colossal Biosciences. He served on the board of directors of Edico Genome Inc. from March 2014 until its acquisition by Illumina in 2018 and Patara Pharma from October 2014 until its acquisition by Roivant Sciences in 2018. Mr. Szekeres received his undergraduate degree in criminology, law and society from the University of California, Irvine and his J.D. from Duke University School of Law.
- Lisa Peraza
Lisa Peraza，2014年加入Heron担任高级董事、财务总监。Peraza女士于2019年升任副总裁、财务总监，于2020年10月升任副总裁、首席会计官。她拥有20多年的财务和会计经验，主要在生物技术行业。2008年6月至2014年3月，Peraza女士在Ardea Biosciences, Inc.担任关键财务和会计职务，最近担任执行董事、财务总监。2001年6月至2008年5月，在La Jolla Pharmaceutical Company担任重要会计职务。Peraza女士的职业生涯始于毕马威会计师事务所。她获得了加州大学圣巴巴拉分校的学士学位，并获得了加利福尼亚州的注册会计师执照。
Lisa Peraza,has served as Vice President, Finance since August 2024. She has more than 25 years of finance and accounting experience, primarily in the biotechnology industry. Ms. Peraza was most recently Vice President, Chief Accounting Officer at Heron Therapeutics, Inc., a commercial-stage biotechnology company, until March 2024. Prior to joining Heron in 2014, she held key finance and accounting positions at Ardea Biosciences, Inc. and La Jolla Pharmaceutical Company. Ms. Peraza began her career with KPMG LLP. She received a B.A. degree from the University of California, Santa Barbara and is a licensed Certified Public Accountant in the State of California.- Lisa Peraza，2014年加入Heron担任高级董事、财务总监。Peraza女士于2019年升任副总裁、财务总监，于2020年10月升任副总裁、首席会计官。她拥有20多年的财务和会计经验，主要在生物技术行业。2008年6月至2014年3月，Peraza女士在Ardea Biosciences, Inc.担任关键财务和会计职务，最近担任执行董事、财务总监。2001年6月至2008年5月，在La Jolla Pharmaceutical Company担任重要会计职务。Peraza女士的职业生涯始于毕马威会计师事务所。她获得了加州大学圣巴巴拉分校的学士学位，并获得了加利福尼亚州的注册会计师执照。
- Lisa Peraza,has served as Vice President, Finance since August 2024. She has more than 25 years of finance and accounting experience, primarily in the biotechnology industry. Ms. Peraza was most recently Vice President, Chief Accounting Officer at Heron Therapeutics, Inc., a commercial-stage biotechnology company, until March 2024. Prior to joining Heron in 2014, she held key finance and accounting positions at Ardea Biosciences, Inc. and La Jolla Pharmaceutical Company. Ms. Peraza began her career with KPMG LLP. She received a B.A. degree from the University of California, Santa Barbara and is a licensed Certified Public Accountant in the State of California.
- Jeff Cohn
Jeff Cohn，自2024年9月起担任总法律顾问和公司秘书。他在法律、商业和生命科学领域拥有超过15年的丰富经验。他最近在Vir Biotechnology, Inc.担任公司法副总裁，Vir Biotechnology, Inc.是一家临床阶段的生物制药公司，专注于严重的传染病和癌症。在此之前，从2016年到2023年，他在Heron Therapeutics， Inc.担任越来越重要的职位，最近担任执行董事、助理总法律顾问和助理秘书。此前，他还在Becton， Dickinson and Company和Life Technologies Corporation担任重要职务。他的职业生涯始于Faegre Drinker Biddle & Reath LLP（前身为Faegre Baker Daniels LLP）的企业合伙人。他获得了Indiana大学凯利商学院的商业经济学、公共政策和创业双学士学位，以及Indiana大学罗伯特·h·麦金尼法学院的法律学位。
Jeff Cohn,has served as General Counsel and Corporate Secretary since September 2024. He has more than 15 years of extensive legal, business and life sciences experience. Mr. Cohn was most recently Vice President, Corporate Law at Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company focused on serious infectious diseases and cancer. Prior to that, he held key positions of increasing responsibility at Heron Therapeutics, Inc. from 2016 until 2023, most recently serving as Executive Director, Assistant General Counsel and Assistant Secretary. He also previously held key positions of increasing responsibility at Becton, Dickinson and Company and Life Technologies Corporation. He began his career as a corporate associate at Faegre Drinker Biddle & Reath LLP (formerly Faegre Baker Daniels LLP). Mr. Cohn earned dual B.S. degrees in Business Economics and Public Policy and Entrepreneurship from the Indiana University Kelley School of Business and his law degree from the Indiana University Robert H. McKinney School of Law.- Jeff Cohn，自2024年9月起担任总法律顾问和公司秘书。他在法律、商业和生命科学领域拥有超过15年的丰富经验。他最近在Vir Biotechnology, Inc.担任公司法副总裁，Vir Biotechnology, Inc.是一家临床阶段的生物制药公司，专注于严重的传染病和癌症。在此之前，从2016年到2023年，他在Heron Therapeutics， Inc.担任越来越重要的职位，最近担任执行董事、助理总法律顾问和助理秘书。此前，他还在Becton， Dickinson and Company和Life Technologies Corporation担任重要职务。他的职业生涯始于Faegre Drinker Biddle & Reath LLP（前身为Faegre Baker Daniels LLP）的企业合伙人。他获得了Indiana大学凯利商学院的商业经济学、公共政策和创业双学士学位，以及Indiana大学罗伯特·h·麦金尼法学院的法律学位。
- Jeff Cohn,has served as General Counsel and Corporate Secretary since September 2024. He has more than 15 years of extensive legal, business and life sciences experience. Mr. Cohn was most recently Vice President, Corporate Law at Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company focused on serious infectious diseases and cancer. Prior to that, he held key positions of increasing responsibility at Heron Therapeutics, Inc. from 2016 until 2023, most recently serving as Executive Director, Assistant General Counsel and Assistant Secretary. He also previously held key positions of increasing responsibility at Becton, Dickinson and Company and Life Technologies Corporation. He began his career as a corporate associate at Faegre Drinker Biddle & Reath LLP (formerly Faegre Baker Daniels LLP). Mr. Cohn earned dual B.S. degrees in Business Economics and Public Policy and Entrepreneurship from the Indiana University Kelley School of Business and his law degree from the Indiana University Robert H. McKinney School of Law.
- Raúl Collazo
Raúl Collazo，自2021年起担任副总裁、全球医疗事务和战略主管。他在小型生物技术和大型制药境中拥有超过25年的医疗事务经验。此外，他还通过自己的咨询公司为商业化前的生命科学公司提供医疗/科学事务、合规、运营和企业战略方面的咨询。在加入Connect之前，他曾在多个组织担任高级领导职务，包括从2020年到2021年在Skysis/Fishawack Health（现为Avalere Health， LLC）担任首席医疗事务主管，以及从2018年到2020年在Biotheranostics， Inc.（一家被Hologic， Inc.收购的肿瘤诊断公司）担任医疗和科学事务副总裁。在职业生涯早期，他曾担任胃肠病学、皮肤病学、炎症性疾病、肿瘤学、糖尿病/肥胖和神经病学领域的几家公司的医疗事务主管。他在Oregon大学获得神经生理学博士学位，并在加州大学圣地亚哥医学院完成博士后培训。
Raúl Collazo,has served as Vice President, Global Head of Medical Affairs and Strategy since 2021. He has over 25 years of Medical Affairs experience in small biotech and large pharmaceutical environments. Additionally, he has extensive expertise advising pre-commercial life science companies on medical/scientific affairs, compliance, operations, and corporate strategy through his own consulting firm. Prior to joining Connect, he served in senior leadership positions in various organizations, including Principal, Head of Medical Affairs at Skysis/Fishawack Health (now Avalere Health, LLC) from 2020 until 2021 and Vice President, Medical and Scientific Affairs at Biotheranostics, Inc., an oncology diagnostics company acquired by Hologic, Inc., from 2018 until 2020. Earlier in his career, Dr. Collazo served as Head of Medical Affairs for several companies working in the areas of gastroenterology, dermatology, inflammatory diseases, oncology, diabetes/obesity, and neurology. He earned his Ph.D. in Neurophysiology from the University of Oregon and completed postdoctoral training at the University of California, San Diego School of Medicine.- Raúl Collazo，自2021年起担任副总裁、全球医疗事务和战略主管。他在小型生物技术和大型制药境中拥有超过25年的医疗事务经验。此外，他还通过自己的咨询公司为商业化前的生命科学公司提供医疗/科学事务、合规、运营和企业战略方面的咨询。在加入Connect之前，他曾在多个组织担任高级领导职务，包括从2020年到2021年在Skysis/Fishawack Health（现为Avalere Health， LLC）担任首席医疗事务主管，以及从2018年到2020年在Biotheranostics， Inc.（一家被Hologic， Inc.收购的肿瘤诊断公司）担任医疗和科学事务副总裁。在职业生涯早期，他曾担任胃肠病学、皮肤病学、炎症性疾病、肿瘤学、糖尿病/肥胖和神经病学领域的几家公司的医疗事务主管。他在Oregon大学获得神经生理学博士学位，并在加州大学圣地亚哥医学院完成博士后培训。
- Raúl Collazo,has served as Vice President, Global Head of Medical Affairs and Strategy since 2021. He has over 25 years of Medical Affairs experience in small biotech and large pharmaceutical environments. Additionally, he has extensive expertise advising pre-commercial life science companies on medical/scientific affairs, compliance, operations, and corporate strategy through his own consulting firm. Prior to joining Connect, he served in senior leadership positions in various organizations, including Principal, Head of Medical Affairs at Skysis/Fishawack Health (now Avalere Health, LLC) from 2020 until 2021 and Vice President, Medical and Scientific Affairs at Biotheranostics, Inc., an oncology diagnostics company acquired by Hologic, Inc., from 2018 until 2020. Earlier in his career, Dr. Collazo served as Head of Medical Affairs for several companies working in the areas of gastroenterology, dermatology, inflammatory diseases, oncology, diabetes/obesity, and neurology. He earned his Ph.D. in Neurophysiology from the University of Oregon and completed postdoctoral training at the University of California, San Diego School of Medicine.
- Kimberly J. Manhard
Kimberly J. Manhard，曾担任Heron Therapeutics， Inc.自2016年起担任药物开发执行副总裁，并于2014年和2015年以及2019年至2023年2月再次担任董事。Manhard女士在药物开发、监管事务和制药运营方面拥有超过25年的经验。从2008年到2016年，她担任Ardea Biosciences， Inc.的监管事务和开发运营高级副总裁。在Ardea任职期间，Manhard女士在Zurampic（lesinurad）的开发和2015年监管批准中发挥了重要作用。在2006年加入Ardea之前，她是她自己的咨询公司的总裁，Exelixis, Inc.的监管事务副总裁，并在Agouron Pharmaceuticals， Inc. （Warner-Lambert Company的一个部门）担任多个监管职位，支持抗癌和抗病毒产品的开发和商业化，包括Viracept（nelfinavir）。Manhard女士此前也曾任职Bristol-Myers Squibb Company，负责监管事务，负责肿瘤化合物，包括紫杉醇（Taxol）和传染病化合物，包括Videx（didanosine）和Zerit。她的职业生涯始于Eli Lilly and Company和G.H. Besselaar Associates （Covance Inc.）的临床研究。自2020年以来，Manhard女士还担任InhibRx， Inc.（专注于癌症新疗法的研究和开发）的董事。Manhard女士是the Fleet Science Center的董事会成员。她在Florida大学获得动物学学士学位和法语学士学位。
Kimberly J. Manhard,has served as Heron Therapeutics, Inc. Executive Vice President, Drug Development since 2016, and served as a director in 2014 and 2015 and again from 2019 to February 2023. Ms. Manhard has more than 25 years of experience in drug development, regulatory affairs and pharmaceutical operations. From 2008 to 2016, she served as the Senior Vice President of Regulatory Affairs and Development Operations at Ardea Biosciences, Inc. In her role at Ardea, Ms. Manhard was instrumental in the development and 2015 regulatory approval of Zurampic (lesinurad). Prior to joining Ardea in 2006, she was President of her own consultancy firm, Vice President of Regulatory Affairs for Exelixis, Inc. and held multiple regulatory positions at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company, supporting development and commercialization of anticancer and antiviral products, including Viracept (nelfinavir). Ms. Manhard was also previously with Bristol-Myers Squibb Company in regulatory affairs, responsible for oncology compounds, including Taxol (paclitaxel) and infectious disease compounds, including Videx (didanosine) and Zerit (stavudine). She began her career in clinical research with Eli Lilly and Company and G.H. Besselaar Associates (Covance Inc.). Since 2020, Ms. Manhard has also served as a director of InhibRx, Inc., which is focused on the research and development of new treatments for cancer. Ms. Manhard is a member of the board of trustees for the Fleet Science Center. She received a B.S. degree in zoology and a B.A. degree in French from the University of Florida.- Kimberly J. Manhard，曾担任Heron Therapeutics， Inc.自2016年起担任药物开发执行副总裁，并于2014年和2015年以及2019年至2023年2月再次担任董事。Manhard女士在药物开发、监管事务和制药运营方面拥有超过25年的经验。从2008年到2016年，她担任Ardea Biosciences， Inc.的监管事务和开发运营高级副总裁。在Ardea任职期间，Manhard女士在Zurampic（lesinurad）的开发和2015年监管批准中发挥了重要作用。在2006年加入Ardea之前，她是她自己的咨询公司的总裁，Exelixis, Inc.的监管事务副总裁，并在Agouron Pharmaceuticals， Inc. （Warner-Lambert Company的一个部门）担任多个监管职位，支持抗癌和抗病毒产品的开发和商业化，包括Viracept（nelfinavir）。Manhard女士此前也曾任职Bristol-Myers Squibb Company，负责监管事务，负责肿瘤化合物，包括紫杉醇（Taxol）和传染病化合物，包括Videx（didanosine）和Zerit。她的职业生涯始于Eli Lilly and Company和G.H. Besselaar Associates （Covance Inc.）的临床研究。自2020年以来，Manhard女士还担任InhibRx， Inc.（专注于癌症新疗法的研究和开发）的董事。Manhard女士是the Fleet Science Center的董事会成员。她在Florida大学获得动物学学士学位和法语学士学位。
- Kimberly J. Manhard,has served as Heron Therapeutics, Inc. Executive Vice President, Drug Development since 2016, and served as a director in 2014 and 2015 and again from 2019 to February 2023. Ms. Manhard has more than 25 years of experience in drug development, regulatory affairs and pharmaceutical operations. From 2008 to 2016, she served as the Senior Vice President of Regulatory Affairs and Development Operations at Ardea Biosciences, Inc. In her role at Ardea, Ms. Manhard was instrumental in the development and 2015 regulatory approval of Zurampic (lesinurad). Prior to joining Ardea in 2006, she was President of her own consultancy firm, Vice President of Regulatory Affairs for Exelixis, Inc. and held multiple regulatory positions at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company, supporting development and commercialization of anticancer and antiviral products, including Viracept (nelfinavir). Ms. Manhard was also previously with Bristol-Myers Squibb Company in regulatory affairs, responsible for oncology compounds, including Taxol (paclitaxel) and infectious disease compounds, including Videx (didanosine) and Zerit (stavudine). She began her career in clinical research with Eli Lilly and Company and G.H. Besselaar Associates (Covance Inc.). Since 2020, Ms. Manhard has also served as a director of InhibRx, Inc., which is focused on the research and development of new treatments for cancer. Ms. Manhard is a member of the board of trustees for the Fleet Science Center. She received a B.S. degree in zoology and a B.A. degree in French from the University of Florida.